• Sunday, August 6, 2023 @ 12:00 am


H1 2023 results driven by strong GI Genius, Lialda, and Contract manufacturing growth. Cosmo will repay EUR 175 mn convertible bonds in November 2023 with cash. FY 2023 guidance was maintained despite USD headwind signaling a strong H2 boosted by strong upfront and sales milestones for Winlevi with several new agreements underway.

Key catalysts include:

  • CB-01-33 start POC trial in bile acid diarrhea (H2 2023)
  • Winlevi licensing agreements (during 2023)
  • Winlevi filing for EU approval (H2 2023)

To the full Cosmo Valuation Report

You may also be interested in